BSH 2017 | How is the landscape of Hodgkin lymphoma therapy changing?
Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses changes in the landscape of Hodgkin lymphoma therapy at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains that because of the high curability of Hodgkin lymphoma, research was not focused on developing new therapies. However, Prof. Younes speaks about two new drugs which have recently changed how Hodgkin lymphoma is treated, the antibody-drug conjugate brentuximab vedotin and immune checkpoint inhibitors, and discusses their mechanisms of action and how they can be combined. He also discusses which factors need to be considered for new therapies, including value and long-term safety.
Get great new content delivered to your inboxSign up